Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 18.0-39.0,  Suppression of Ovulation Good general overall health with no chronic medical conditions that result in periodic exacerbations that require significant medical care. 2. Age 18-39 years, inclusive, at the enrollment visit. 3. Have a regular menstrual cycle 21-35 days in duration when not using hormonal contraception 4. Have an intact uterus and both ovaries. 5. Able and willing to comply with the protocol and sign an informed consent. 6. Consistent use of effective contraception during the preceding cycle (note: women who use oral, transdermal, vaginal, implantable or intrauterine hormonal contraceptives in the preceding cycle must have discontinued at least 7 days prior to start of treatment and not had unprotected intercourse since discontinuing the method). 7. Not at high risk for pregnancy, defined as consistently using a non-hormonal method of contraception (including Copper IUDs); have a surgically sterile male partner with a vasectomy; be abstinent; or be in a same-sex relationship from the start of treatment through study exit (including recovery period). 8. Have a negative pregnancy test at the admission visit. 9. Have a diastolic blood pressure (BP) ≤85 mm Hg and systolic BP ≤135 mm Hg after 5 minutes rest in sitting position at the admission visit. 10. Willing to abstain from use of non-water based vaginal lubricant during the study  Participating in another clinical trial involving an investigational product within the last 30 days (prior to screening) or planning to participate in another clinical trial during this study. 2. Not living in the catchment area of the study site. 3. Known hypersensitivity to progestins or estrogen. 4. Contraindications to combined estrogen-progestin contraceptive use including Thrombophlebitis or thromboembolic disorders Past personal history of deep vein thrombophlebitis or thromboembolic disorders History of venous thrombosis or embolism in a first-degree relative <55 years of age suggesting familial defect in blood coagulation system History of thrombosis or embolism OR any other personal or family history which in the opinion of the investigator suggests increased risk History of stroke Known or suspected carcinoma of the breast Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia Undiagnosed abnormal genital bleeding Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use